Journal Basic Info

  • Impact Factor: 2.709**
  • H-Index: 11 
  • ISSN: 2474-1663
  • DOI: 10.25107/2474-1663
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Surgical Oncology
  •  Chemoprevention
  •  Central Nervous System Tumors
  •  Palliative Care
  •  Stomach Cancer
  •  Leukemia
  •  Urological Cancers
  •  Melanoma/Skin Cancer

Abstract

Citation: Clin Oncol. 2020;5(1):1718.DOI: 10.25107/2474-1663.1718

APC and EGFR Proteins Expression in Gliomas

Nahla E Abdelraheem, Alsadig Gassoum, Sawsan Ahmed Hamed AL-Deaf, Nihad Elsadig Babiker, Lamyaa A Elhassan, Mohamad Abdelrahman Arbab and Imad Fadl-Elmula

Department of Histotechnology, National Center for Neurological Sciences (NCNS), Sudan Department of Immunology, National Center for Neurological Sciences (NCNS), Sudan CNS Surgeon, National Center for Neurological Sciences (NCNS), Sudan Department of Hematology, National Center for Neurological Sciences (NCNS), Sudan Department of Histopathology, National Center for Neurological Sciences (NCNS), Sudan Department of Surgery, University of Khartoum, Sudan Department of Cytogenetics, Assafa academy, Sudan

*Correspondance to: Nahla E Abdelraheem 

 PDF  Full Text Research Article | Open Access

Abstract:

Gliomas are the most common brain neoplasms in adults, accounting for about 70% of primary neoplasms of the Central Nervous System (CNS). Adenomatous Polyposis Coli (APC) is a tumor suppressor protein and one of the key players of the Wnt signaling pathway. Epidermal Growth Factor Receptor (EGFR) is an ErbB receptor with tyrosine kinase activity. EGFR over expression and activation can impact cancer cell survival, proliferation and invasion. The study was aimed to assess the possibility of using APC and EGFR proteins as markers for gliomas. Sixty-one tumor tissues were processed to obtain paraffin embedded blocks, 3 µm were cut and stained for APC and EGFR proteins immunohistochemistry. APC protein immunohistochemical staining showed cytoplasmic expression in 57.4% of the samples with over expression in 9.9%. EGFR protein immunohistochemical staining showed cytoplasmic expression in 31.1%, and membranous in 1.6% with over expression in 6.5% of the samples. APC was expressed mostly in astrocytoma I (19.7%), astrocytoma II (18%), ependymoma (1.6%) and Pleomorphic Xanthoastrocytoma (PXA) (1.6%) with over expression in Glioblastoma (GBM) (3%). EGFR was expressed in Astrocytoma I (9.8%) and astrocytoma II (14.8%) with over expression in of GBM (1.6%). Statistically there was no significant relationship between the Grades of gliomas and immune staining score of APC and EGFR proteins (P-value = 0.667 and 0.128, respectively). APC and EGFR proteins show both cytoplasmic and membranous expression in glioma and being over expressed in high grades of astrocytoma which suggests the possibility of using them as prognostic markers for astrocytoma

Keywords:

Gliomas; APC; EGFR; Immunohistochemistry

Cite the Article:

Abdelraheem NE, Gassoum A, Hamed AL-Deaf SA, Babiker NE, Elhassan LA, Arbab MA, et al. APC and EGFR Proteins Expression in Gliomas. Clin Oncol. 2020; 5: 1718.

Search Our Journal

Journal Indexed In

Articles in PubMed

LINGO-1 is a New Therapy Target and Biomarker for Ewing Sarcoma
 PubMed  PMC  PDF  Full Text
Metastatic Retroperitoneal Paraganglioma: Case Report and Review of the Literature
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Dosimetric Comparison of IMRT, Hybrid IMRT and Hybrid VMAT for Early Stage Right-Sided Breast Cancer
 Abstract  PDF  Full Text
Cardiovascular Screening and Prevention in Female Breast Cancer Patients Receiving Radiotherapy
 Abstract  PDF  Full Text
View More...